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a b s t r a c t
To the best of our knowledge, two phosphorylation sites have been reported previously, among 11 known
Vaccinia virus phosphoproteins. Here, via phosphopeptide mass spectrometry, up to 189 phosphorylation
sites were identiﬁed among 48 proteins in preparations of puriﬁed Vaccinia mature virus (MV). 8.5% of
phospho-residues were pTyr. Viral phosphoproteins were found in diverse functional classes, including
structural proteins, membrane proteins and RNA polymerase subunits. Among the nine identiﬁed
membrane phosphoproteins, the sites in just one, namely A14L, were deduced to be internal with respect
to the accompanying membrane. Examination of sites in known substrates of the Vaccinia-encoded
protein kinase VPK2, indicated VPK2 to be a proline-dependent kinase. The MV phosphoproteome was
enriched in potential substrates of cellular kinases belonging to the CDK2/CDK3, CK2, and p38 groups.
Quantitative mass spectrometry identiﬁed several sites that became phosphorylated during intravirion
kinase activation in vitro, each showing one of two distinct pH-dependency proﬁles.
& 2014 Elsevier Inc. All rights reserved.
Introduction
More than 40 years has passed since the ﬁrst demonstration of
phosphoproteins in the Vaccinia virion (Rosemond and Moss,
1973; Sarov and Joklik, 1972), yet in the interim only a handful
of Vaccinia phosphoproteins and even fewer phosphorylation sites
therein have been reported. With so little known of phosphoryla-
tion targets in Vaccinia proteins, it seems necessary to brieﬂy
recap the entire 40 years: Accordingly, from the early ﬁnding that
virion uncoating (using non-ionic detergent plus sulfhydryl redu-
cing agent) in the presence of γ32P-ATP led to the incorporation of
32P into hot TCA precipitable material (Paoletti and Moss, 1972),
initial studies focused largely on protein kinase activity present
within the virion. This activity could phosphorylate endogenous
proteins (within the virion core, mainly of low molecular weight)
or exogenous substrates (histones, protamine), with speciﬁcity for
Ser and Thr residues (Paoletti and Moss, 1972). Protein kinase
activity could be solubilized from whole virions (Kleiman and
Moss, 1973) or virion cores and, with puriﬁcation, core-derived
kinase was increasingly dependent upon the virion membrane
fraction (Kleiman and Moss, 1973) or acceptor proteins therefrom
(Kleiman and Moss, 1975b). Kinase activity was associated with
a polypeptide of 62 kDa molecular weight (Kleiman and Moss,
1975b) with an alkaline pH optimum (Kleiman and Moss, 1975a;
Paoletti and Moss, 1972), and was activated by protamine (Kleiman
and Moss, 1975a). Substrates were phosphorylated at (mainly)
serine and threonine residues (Kleiman and Moss, 1975a).
Subsequently, Vaccinia gene B1R was shown to encode a 34.2 kDa
essential protein with homology to the catalytic domains of numerous
protein kinases (Howard and Smith, 1989; Lin et al., 1992; Rempel and
Traktman, 1992; Traktman et al., 1989). Bacterially-expressed GST-B1R
could phosphorylate exogenous substrates including casein and his-
tones H1, H2B and H3, recombinant 6His-B1R at Ser/Thr residues
(Mercer and Traktman, 2005) and it's own GST moiety at Thr residues
(Banham and Smith, 1992; Lin et al., 1992; Rempel and Traktman,
1992). B1R kinase (also referred to as vaccinia protein kinase 1, or
VPK1) was shown to be associated with the virus particle—mainly
the core (Banham and Smith, 1992; Lin et al., 1992). In core extracts,
however, the chromatographic separation of bulk casein kinase
activity from endogenous B1R protein indicated the presence of
additional kinases in the particle (Lin et al., 1992). The major portion
of core kinase activity was subsequently attributed to a second
essential S/T protein kinase (“VPK2”) encoded by Vaccinia late gene
F10L (Lin and Broyles, 1994). This 50-kDa polypeptide could phosphor-
ylate α-casein primarily at Ser residues as well as a casein kinase
I-speciﬁc peptide substrate, myelin basic protein, and itself through
autophosphorylation (Mercer and Traktman, 2005). VPK2 also binds
phosphoinositides (Punjabi and Traktman, 2005). VPK2 expression
and autophosphorylation occur late during infection (Punjabi and
Traktman, 2005), and VPK2 is tightly associated with membranes
(Punjabi and Traktman, 2005). While VPK1 is structurally related to a
group of cellular kinases (the “VRKs” (Nezu et al., 1997)), the only
known phylogenetic relatives of VPK2 are homologs from other
poxviruses (Punjabi and Traktman, 2005).
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Roles of VPK1 and VPK2 are likely complex: Both kinases are
essential for Vaccinia viability (Jacob et al., 2011; Lin and Broyles,
1994; Rempel and Traktman, 1992). VPK1 is expressed early during
infection (Rempel and Traktman, 1992) and can later be found in
viral factories (Banham and Smith, 1992) and within the virion.
Temperature-sensitive (ts) mutants in VPK1 arrest at or prior to
the DNA replication stage of infection under non-permissive
conditions (Rempel and Traktman, 1992; Traktman et al., 1989),
and VPK1 may have an additional role in Vaccinia intermediate
transcription by relieving the cellular inhibition of intermediate
gene promoters (Ibrahim et al., 2013). ts Mutants in VPK2, on the
other hand, are blocked in virion morphogenesis at an early stage
of virion assembly (Wang and Shuman, 1995), and VPK2's catalytic
activity is required to overcome this block (Szajner et al., 2004).
VPK2 contributes to a complex of seven proteins required for the
earliest stages of virion morphogenesis (namely the association of
membranes and viroplasm) (Szajner et al., 2004).
In addition to the roles of VPK1 and 2 deﬁned via genetic
approaches (above), biochemical experiments have indicated that
protein phosphorylation events in the virion core, at the very outset
of infection, activate early gene transcription within the infecting virus
particle. Speciﬁcally, while the activation of puriﬁed cores in vitro is
associated with a 2min lag in the start of early gene transcription,
this lag is abolished by the pre-incubation of cores with ATP. Moreover,
protein phosphorylation progresses linearly during this 2min
window without a lag (Moussatche and Keller, 1991). At least 12
distinct virion proteins were shown to become phosphorylated
during this time window according to SDS-PAGE autoradiograms
(Moussatche and Keller, 1991), with the majority of 32P label incorpo-
rated into low molecular weight proteins. By pre-incubation at pH
7.0 instead of pH 8.5 and in the presence of limiting ATP, the lag was
restored and two proteins (70, 80 kDa) speciﬁcally failed to became
phosphorylated (Moussatche and Keller, 1991).
In addition to the two identiﬁed protein kinases (above),
Vaccinia encodes (Guan et al., 1991) and encapsidates (Liu et al.,
1995) a dual speciﬁcity protein phosphatase (“VH1”, the prototypic
member of the dual-speciﬁcity phosphatase class). Upon repres-
sion of VH1 expression, virions are produced normally during
infection but with greatly reduced infectivity due to their inability
to transcribe early genes (Liu et al., 1995). A 1.32 Å crystal structure
shows VH1 to be a homodimer (Koksal et al., 2009).
Which Vaccinia proteins are known to be phosphorylated?
Table 1 lists the eleven Vaccinia proteins (and two residues) shown
to be phosphorylated prior to the current study, and Table S1
summarizes in detail prior studies of Vaccinia protein phosphor-
ylation, along with associated description (Supplementary intro-
duction). With regard to host (cellular) protein substrates: Proteins
S2 and Sa of the 40S ribosomal subunit have been identiﬁed
as VPK1 substrates (Banham et al., 1993). In addition, a story is
emerging in which kinases/phosphatase carried by the particle
may have roles in inﬂuencing cellular signaling, speciﬁcally innate
defenses early during infection (Supplementary introduction).
Here, we have characterized the phosphoproteome of the
Vaccinia virus particle identifying, conservatively, 189 sites of
phosphorylation among 48 proteins. We have also characterized
VPK2's consensus binding site, along with candidate cellular
kinases contributing to the virion phosphoproteome. Further, we
have examined dynamic changes in phosphorylation upon activa-
tion of the virus particle in vitro and the pH-dependency thereof.
Our data address and extend a number of the above-described
prior observations of Vaccinia protein phosphorylation.
Results
MV proteome: A meta-analysis
Three MS studies of the Vaccinia virion proteome have been
published (Chung et al., 2006; Resch et al., 2007; Yoder et al., 2006).
As a baseline for investigation of the virion phosphoproteome (below),
we assayed the proteome of our own preparation of mature virus
(MV) of Vaccinia strain WR. Table S2 shows a comparison of the four
resulting virion proteome studies (three of strainWR, one Copenhagen
strain) and Fig. 1 shows a meta-analysis of Table S2. Of the 217 unique
protein accessions comprising the current UniProt reference proteome
for Vaccinia strain WR, 53 were unanimously identiﬁed as MV-
associated in all four studies, 112 were unanimously not found to be
virion-associated in any of the four MS studies. The latter group of
proteins includes G5R, a FEN1-like nuclease (Senkevich et al., 2009),
which was found to be virion-associated by immunoblotting (da
Fonseca et al., 2004), a technique that is arguably more sensitive than
MS. 20 additional Vaccinia proteins were found by just one of the four
groups of investigators, and 32 further Vaccinia proteins by two or
three groups. The above numbers attest to a core proteome whose
abundance is above the minimum threshold for detection by all
groups combined with, perhaps, differential sensitivity/analysis depth
thresholds among groups for low abundance virion proteins, and/or an
overlapping ﬁelds of contaminants between virus preparations.
MV phosphoproteome: Approach and thresholding
We next investigated protein phosphorylation in the Vaccinia
virion. Fig. 2 summarizes the strategies implemented. Overall, a
“bottom-up” approach was taken, in which puriﬁed Vaccinia MV
was disaggregated prior to tryptic digestion and enrichment for
phosphopeptides. Peptides and phosphorylation sites were then
identiﬁed via nanoLC-MS/MS. In some experiments, prior to disag-
gregation and digestion, aliquots of puriﬁed MV were “activated” by
Table 1
Eleven vaccinia proteins shown to be phosphorylated prior to the current MS-based study.
Protein Packaged? Residue(s) phosphorylated in infected cells
F17R Y pSer
A17L Y pSer, pThr and pTyr; Y203
A14L Y Ser residues; S85
F10 (VPK2) Y Thr residues
A30L Y Ser residues
G7L Y Ser residues
H5R Y Thr residues. Recombinant H5R is phosphorylated by
recombinant VPK1 in vitro at Thr84 and Thr85
A13 Y Ser residues, (Ser 40?)
I3 Y Ser residues
A11R Probably
E8R Y
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incubation under conditions intended to either uncoat or simulta-
neously uncoat/activate intravirion kinases. In such cases, the tryptic
digestion products of activated virions and associated controls were
differentially labeled with stable isotopes prior to pooling, phospho-
peptide enrichment and nanoLC-MS/MS with quantitative analysis
of isotopically offset mass clusters in mass spectra at the precursor-
peptide level (Chou et al., 2012). In order to maximize the diversity of
phosphopeptides identiﬁed, as well as conﬁdence in the localization of
phosphate groups within phosphopeptides, replicate experiments
were accompanied by a “strategy of variation” employing variously
sized aliquots of MV, a variety of phosphopeptide enrichment techni-
ques (phases, supports, strategies) and elution solvents (Fig. 2), two
distinct mass spectrometers, various data-dependent spectral acquisi-
tion strategies and peptide dissociation methods inside the mass
spectrometer, and various database search parameters (tryptic or
semi-tryptic cleavage speciﬁcity, 7deamidation, 7isotope error
mode (0-13C or 1-13C): All Mascot search, report and export para-
meters are given in Supplementary methods, Table S6). We chose the
most conservative scoring thresholds (Table S6) for our ﬁnal dataset in
order to minimize “noise” that may arise from ambiguous phosphosite
localization within peptides whose identiﬁcation as phosphopeptides
might nonetheless be considered conﬁdent (see Table S6 legend). Our
chosen threshold criterion was 1% homology FDR (false-discovery rate
in target-decoy searches, see “Materials and methods” section and
legend to Table S6). A 1% threshold can be regarded as an indication of
99% statistical conﬁdence that peptides were correctly identiﬁed. Via
use of a stringent threshold, a number of high-conﬁdence phospho-
peptides may have been excluded from the ﬁnal dataset whose site
localization within the peptide was less conﬁdent.
Overall interpretation of virion phosphopeptide data
Table S3 shows the complete dataset of virion-derived phos-
phopeptides exceeding the conservative 1% homology FDR thresh-
old, from 12 analyses of seven phosphopeptide samples. In
Table S4, the dataset of Table S3 has been condensed to show just
one row per identiﬁed phosphopeptide positional isomer. Filtering
criteria used in the condensation of Tables S3 and S4 are given in
“Supplementary methods”. Fig. S1 shows the phosphopeptides of
Table S4 aligned against complete protein sequences of the
Vaccinia proteome. The conservative MV phosphoproteome
(Table S4, Fig. S1) covered 189 sites of phosphorylation among
48 Vaccinia virus accessions. Since the seven phosphopeptide
samples included two from experiments designed to activate the
virion-packaged kinases (see below), then the listings in Tables S3
and S4 may include a few sites detected only as a result of their
having become phosphorylated during in vitro activation.
Among the 48 Vaccinia accessions, 27 were shared with the 53-
member consensus virion proteome (above), and 10 were from the
112-member group of proteins not previously detected in the MV
proteome by any of the four sets of investigators (above). These 10
included: Uncharacterized protein 18 (from the left end of the
genome); N2L/BCL2-like; A1L/VLTF2; A23R/VITF3; A44L (3 beta-
hydroxysteroid dehydrogenase/Delta 5-4-isomerase); A47L
(inferred); B8R (soluble interferon gamma receptor); B13R/SPI2;
B18R (ANK repeat protein) and small open reading frame (ORF)
YVDA (Table S2). From the perspective of Vaccinia lifecycle, none
of these 10 has an obvious role within the infectious mature virion.
Alternative sites of phosphorylation vs. localization ambiguities
The experiments of this study were tasked with not only the
conﬁdent identiﬁcation of phosphopeptides, but also the conﬁdent
localization of phosphorylated residue(s) therein. For phosphopeptides
containing multiple potential acceptor sites, scoring methods for the
accuracy of phosphate localization remain a subject of debate in the
ﬁeld (Chalkley and Clauser, 2012; Fermin et al., 2013). Here, phospho-
residue assignments were scored according to Mascot's implementa-
tion of reference (Savitski et al., 2011) based on numbers of distin-
guishing fragmentation ions between possible phospho-positional
isomers (“Materials and methods”). Resulting scores, referred to here
as “site_analysis conﬁdence” (SAC), represent conﬁdence (%) that a
given site is the correct one. In our conservatively-thresholded
phosphopeptide dataset, we adopted a liberal interpretation, namely
that the listed positional isomers were, except when arising from the
same Mascot query of the same precursor ion in the same mass
spectrum, genuinely alternative phosphate positions. Reasons for this
interpretation are expounded in Supplementary materials.
Proportion of pSer, pThr and pTyr sites in the MV phosphoproteome
Of the 189 phosphorylation sites in the conservatively-thresholded
MV phosphoproteome, 121, 151 and 16 sites (64.4%, 27.1% and 8.5%)
represented pSer, pThr and pTyr residues, respectively. The content of
pTyr was markedly higher than the 0.05% estimate for tyrosine
phosphorylation in cellular organisms (Hunter, 1998; Hunter and
Sefton, 1980; Mann et al., 2002). Those estimates, however, pre-date
recent advances in phosphopeptide enrichment and MS. Moreover,
the Vaccinia kinase VPK2 shows speciﬁcity for pTyr (Betakova et al.,
1999; Derrien et al., 1999; Szajner et al., 2004), and Vaccinia proteins
may be predisposed to intersect with cellular signal transduction and
regulation pathways.
Some phosphorylation sites, at least, are only partially occupied in the
virion
To assay for partial occupancy of phosphorylation sites in the
virion, peptides in the TiO2 ﬂowthrough fraction from experiment
“Kinase2” were subjected to SCX (strong cation exchange) fractio-
nation (Fig. 2). In the resulting fractions, non-phosphorylated
counterparts were found for 86 of the 233 phosphopeptide
species in the conservatively-thresholded MV phosphoproteome
(Table S4). These represented 77 of the 189 distinct phosphorylation
sites therein (including sites for which a non-phospho coun-
terpart was found to one but not all nested or overlapping phos-
phopeptides). The presence of non-phosphorylated counterparts to
multiply-phosphorylated phosphopeptides indicated that, in some
protein molecules, multiple sites were simultaneously empty. Rea-
sons for not ﬁnding greater numbers of non-phosphorylated counter-
parts might include 100% site occupancy at other sites, the absence of
Fig. 1. Venn diagram showing overlaps between Vaccinia MV proteomes discov-
ered in four separate MS studies, in terms of numbers of Vaccinia proteins
commonly identiﬁed. One hundred twelve (black box) indicates the number of
proteins from the current Vaccinia reference proteome not found to be virion-
associated in any of the four studies.
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an exhaustive search, and/or technical factors such as sensitivity of
the analysis and peptide ionizability.
MV phosphoproteome, protein-by-protein
Within the 48-protein conservatively-thresholded MV phos-
phoproteome, phosphorylation was most apparent among mem-
brane proteins (9 proteins), structural/virosomal proteins (11
proteins including F17R) and proteins involved in early transcrip-
tion (8 proteins, mainly RNA polymerase subunits). These and
other protein groups in the MV phosphoproteome are discussed
below with reference to Table S4 and Fig. S1, and their consistency
with prior studies is considered in “Discussion” section.
Membrane proteins
The phosphorylation of nine membrane proteins was detected
in the conservative dataset. Seven of the nine were found in the
MV proteome (unanimously, Table S2), the two exceptions being
proteins A9L and A28L, which were not detected in the Copenha-
gen strain analysis (Yoder et al., 2006). The nine membrane
proteins included: A14L: The phosphorylation of three Ser residues
was detected, in a cluster at the C-terminus. This region of A14L is
considered to be internal with respect to the accompanying
membrane (Condit et al., 2006). A17L: Four phosphorylation sites
(pSer:3; pTyr:1) were detected, towards the N- and C-termini of
the protein. Both ends appear to be external with respect to the
accompanying membrane (Condit et al., 2006). A13L: The phos-
phorylation of six sites was detected within this 70 aa membrane
protein (pSer:5; pThr:1), spanning the region from aa40 to aa69.
This region is likely be external with respect to the accompanying
membrane (Condit et al., 2006). A26L: The phosphorylation of nine
residues was detected in phosphopeptides from protein A26L
(pSer:4; pThr:3; pTyr:2). The membrane topology of A26L is
unclear (Condit et al., 2006). A9L: The phosphorylation of 6 Ser
residues was detected in A9L, all of which cluster towards the C-
terminus. Scoring of replicates of each positional isomer suggests,
Fig. 2. Diversity of experimental workﬂows. “Dissociate, digest, desalt” represents the urea-based dissolution of virions and tryptic digestion of virion proteins to peptides.
Upper panel: MV phosphoproteome experiments without quantitation. Virion phosphopeptides were isolated via either TiO2-based enrichment directly, immobilized metal
afﬁnity chromatography (IMAC), or strong cation exchange (SCX) prior to TiO2-based enrichment. “NaP”¼sodium phosphate buffer. Phosphopeptides were analyzed using
either an LTQ Classic or an LTQ Velos Pro mass spectrometer. Instrument methods for the LTQ Classic were based on a combination of collision-induced dissociation (CID) with
either multistage activation (MSA) or neutral loss MS3 (NL-MS3). Instrument methods for the LTQ Velos Pro were based on either alternating CID and electron transfer
dissociation (ETD) scans, or alternating higher-energy collisional dissociation (HCD) and ETD scans. Center panel: Virions were treated under two alternative sets of conditions
designed to activate them to an early transcription-ready state. Peptides generated from the activated (and a third, unactivated) aliquots of virus were subjected to differential
stable isotope-labeling (“light”, “intermediate”, “heavy”) prior to mixing of the labeled samples, phosphopeptide enrichment and nanoLC-MS/MS. Lower panel: Virions were
treated, at two distinct pHs, under conditions expected to activate the intra-virion kinase(s) prior to stable isotope labeling, phosphopeptide enrichment and quantitative
nanoLC-MS/MS. Gray: Non-phosphopeptide fractionation: The TiO2 ﬂow-through fraction from a kinase activation experiment was bound to SCX and 16 salt fractions were each
subjected to nanoLC-MS/MS. Peptides identiﬁed via the 16 resulting database searches were combined into a single “virion non-phosphopeptide” dataset.
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with high probability, that at least some of the 6 Ser residues are
bona ﬁde alternative sites, albeit no conﬁrmatory multiply-
phosphorylated peptides were found. The C-terminal end of A9
would be external with respect to the accompanying membrane
(Condit et al., 2006). L1R: A single pThr was detected in protein
L1R, located close to the protein N-terminus. This region would be
external with respect to the accompanying membrane (Condit
et al., 2006) and presumably in the vicinity of a known myristoyl
group. A28L: One phosphorylation was detected in protein A28L
(pSer at aa48). This residue would be either within the membrane-
spanning region, or just to the external side of it (Condit et al.,
2006). H3L: Five phosphorylation sites were detected within
protein H3L (pSer:1, pThr:3; pTyr:1). Two pairs of sites (one
located around aa20 and the other around aa193 of this 324 aa
protein), are each likely to be alternate positions of a single
phosphate since each pair represents alternative interpretations
of a single Mascot query with equivalent SAC values. Nonetheless,
the possibility that they could be co-chromatographing positional
isomers cannot be discounted. The N-terminal 2/3 of H3L protein
is likely external with respect to the accompanying membrane
(Condit et al., 2006). D8/CAHH: This protein has up to six sites of
phosphorylation (pSer:4; pThr:2) within the C-terminal 53% of the
protein. This region would likely be external with respect to the
accompanying membrane (Condit et al., 2006). Two of the three
adjacent pSer in the region aa204–206 represent alternative
interpretations of a single Mascot query with equivalent SAC
values, in which pSer 205 could be an ambiguous call with pSer
204 and pSer 206 being real.
Irrespective of membrane protein topology (type I, type II and
double membrane-spanning proteins were represented within the
above group of 9 proteins), phosphorylation sites in just one
protein (A14L) were internal with respect to the accompanying
membrane. This indicated that the responsible kinase(s) may be
compartmentalized in the immature or maturing virion, located to
one side only of a morphological stage such as the crescent, or
perhaps at the interface of IV with its external scaffold. In this
regard, immunoEM of IV shows VPK2 localizing to the interior of
the IV membrane (Szajner et al., 2004). Moreover, in infected cells,
immunoﬂuorescence microscopy shows VPK2 localizing to the
perinuclear region, co-localizing with ER- and ERGIC-speciﬁc
markers (Punjabi and Traktman, 2005). Notably, both A14L and
A17L have been indicated to insert co-translationally into the ER
(Rodriguez et al., 1997; Salmons et al., 1997).
Virosomal proteins
All members of the 7-member virosomal “assembly” complex
involved in early virion morphogenesis (comprising proteins A30L,
G7L, VPK2, A15L, D2L, D3R, J1R, (Szajner et al., 2004)) have been
detected in MV (unanimously, Table S2). The MV phosphopro-
teome included three proteins from this complex, namely A30L,
G7L and VPK2. A30L: Two phosphorylation sites were identiﬁed
in protein A30L. They were positional isomers of a single phos-
phopeptide, and mapped towards the protein C-terminus. No
multiply-phosphorylated peptides were available to conﬁrm the
presence of both sites, and while the two sites were not alternative
interpretations of a single Mascot query, nonetheless, the site at
Ser 69 appeared to score more conﬁdently than the site at Ser 57
(Table S3, Mascot expectation score). G7L: Of the eight possible
sites detected in G7L (pSer:2; pThr:6), all lay C-terminal to the two
internal proteolytic processing sites (Condit et al., 2006), i.e.within
the C-terminal 15 kDa segment known to remain associated with
the virion core after processing (Condit et al., 2006). Within this
segment, the 299–315 region of G7L protein contained a cluster of
seven apparent phosphorylation sites (TDGAVTSPLTGNNTITT). The
presence of a diphosphopeptide and a triphosphopeptide in
addition to monophosphopeptides (Tables S3 and S4) supported
the existence of multiple phosphorylations in this cluster (Table
S3). Nonetheless, it is considered possible that T314/T315 repre-
sent the ambiguous localization of a single site. VPK2: VPK2
phosphorylation was detected at three sites (two adjacent Ser,
and one Tyr). The two pSer were each detected in six analyses,
with similar frequency (Table S4), and each showed high con-
ﬁdence (Mascot expectation) scores and similar/high localization
conﬁdence (“Best SAC” values, Table S4). They are therefore
regarded as alternative phosphorylation sites as opposed to
localization ambiguity, though the latter cannot be discounted.
The Tyr phosphorylation scored with lower conﬁdence than did
either pSer.
Phosphorylation was detected in a fourth protein A11R, gen-
erally considered to be virosomal with an early morphogenic role
in viral crescent formation (though apparently not part of the 7-
member complex). This protein, which was reported to not be
encapsidated (Resch et al., 2005), was found in virion preparations
by two groups (Table S2). In the current study, A11R phosphoryla-
tion was detected at two adjacent pSer (S55/S56) and one pThr
(T92). S55/S56 are likely alternate candidate positions for a single
site since they arose from the same Mascot query with the same
expectation score and SAC (Table S3), and no conﬁrmatory multi-
phosphopeptides were detected.
Structural/processed proteins
In addition to the virosomal proteins above, some or all of
which could have a structural role in Vaccinia MV, the phosphor-
ylation of six major structural/processed proteins was detected in
the MV phosphoproteome plus a protein (F17R) that has variously
been described as structural. Within this group of seven proteins,
A3L/p4b, A4L/p39 and A10L/p4a contained the greatest numbers
of identiﬁed phosphorylation sites of any protein in the conserva-
tive dataset, namely 24, 15 and 11 apparent sites, respectively.
Protein L4R/VP8 was not far behind with 8 sites. The relatively
high count of phosphorylation sites identiﬁed in
this group could have been technical in nature, attributable to
the elevated abundance of these proteins in the virion (as
indicated by phosphopeptide “frequency counting”, Supplemen-
tary methods). Several Vaccinia structural proteins undergo pro-
teolytic processing during virion maturation. These include, in
addition to membrane and virosomal proteins A17L and G7L
respectively (above), the major structural proteins A10L/p4a,
A3L/p4b and L4R/VP8, and the processed protein A12L (Condit
et al. (2006) and references therein). Phosphorylation sites were
detected in each of these four proteins (Table S4).
Individually: A10L/p4a is proteolytically processed at two posi-
tions excising a central portion of the protein likely comprising
aa616–697 (Condit et al., 2006; VanSlyke et al., 1991; VanSlyke
et al., 1991). Four phosphorylation sites were detected within the
packaged N-terminal 62 kDa region, along with two apparent
clusters within the packaged C-terminal 23 kDa region (Fig. S1).
The ﬁrst of the latter two clusters comprised four apparent
phosphorylation sites located between residues 732 and 748.
Some of these could be ambiguous site localizations (from the
presence of query groupings, Table S3), albeit the detection of
diphosphopeptides (and triphosphopeptides in the 5% thresholded
dataset, not shown) indicated that two or three, at least, of the
four sites are real. No phosphorylation sites were detected within
the excised (unpackaged) region of p4a. A3L/p4b: Up to 24 sites
were detected in A3L/p4b (pSer:14; pThr:8; pTyr:2). This was the
greatest number of phosphorylation sites detected within a single
protein in the conservative dataset. Nonetheless, a couple of pairs
of sites may be considered to be ambiguous localizations of a
single site, namely, S19/20 and T537/Y544. Proteolytic processing
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upon virus maturation removes a 6 kDa peptide from the N-
terminus of A3L/p4b (Condit et al., 2006). The ﬁnding of a cluster
of three pSer towards the N-terminus therefore indicated the
presence of traces of IV in the MV preparation. L4R/VP8: Of the
eight phosphorylation sites identiﬁed in L4R/VP8 (pSer:7; pTyr:1),
some could be considered ambiguous such as S136/S137 (whose
most likely assignment may be S136). Within the SYSSS cluster at
position 216, the strongest SAC values were recorded at S216 and
S220 (though phosphorylation at each of the Ser residues in this
region cannot be discounted). A 4 kDa peptide is removed from
the N-terminus of L4R/VP8 during proteolytic processing. How-
ever, all phosphorylation sites were found within the C-terminal
(packaged) half of the protein. A12L: This processed protein (which
is likely not a core structural protein) contains four apparent
phosphorylation sites (S79 and T102/T103/S104). Within the latter
cluster, the two most likely locations are T103 and S104 (since the
two assignments to T102 are both split with the more conﬁdent
and abundantly identiﬁed T103, as “query groups”, Table S3). After
removal of 6 kDa from the N-terminus of protein A12L by
proteolytic processing (Condit et al., 2006), all identiﬁed phos-
phorylation sites would lie within the packaged C-terminal region.
In addition to the four proteins described above, three addi-
tional proteins were assigned to the “structural/processed pro-
teins” group, namely, A4L/p39: Up to 15 phoshosites were
identiﬁed in this major structural protein, (pSer:8; pThr:5; pTyr:2),
located in an intensive patch towards the N-terminus, and also
spread through the remainder of the protein. Within the cluster
S14/S15/T16, S14/S15 represents localization ambiguity in which
the phosphate is assignable to either residue. Within the cluster
SSIYY starting at residue S19, S20 appears to be the most probable
position with S19, Y22, Y23 being ambiguous localizations (Table S3).
E11L: A single phosphosite was found in this MV core protein, namely
a pSer adjacent to the C-terminal residue. F17R: Six phosphosites
were detected in protein F17R (pSer:5; pThr;1). The ﬁve pSer
clustered around closely-spaced PSSP and PSSPS motifs in the region
spanning residues 52 to 65. By “frequency-counting” (Supplementary
methods), F17R phosphopeptide VDKPSpSPACER was found to dom-
inate the MV phosphoproteome overall, in absolute abundance
(Tables S3 and S4). S52/53 and S61/62 could each be considered a
pair of ambiguous sites since, for each isomer, some Mascot queries
bifurcated to give alternative interpretations of identical queries and
there were no high-scoring conﬁrmatory multiply-phosphorylated
peptides. Nonetheless, high-scoring queries also existed unequivo-
cally selecting each one of these four phospho positions with high
SAC values (apparently, distinguishing fragment ions were available
in spectra in which the precursor ion was sufﬁciently abundant).
It is therefore concluded that all four Ser residues are alternative sites
of biological phosphate attachment via the liberal interpretation
metric (above).
RNA polymerase and early transcription
Phosphorylation was detected in ﬁve subunits of the 8-Subunit
Vaccinia RNA polymerase, including the two largest subunits (J6R/
RP147 and A24R/RP132—one site apiece, at Ser residues) as well as
three smaller subunits (D7R/RP18, A5R/RP19 and E4L/RP30). One pSer
was detected in D7R/RP18, while phosphorylation of A5R/RP19
included a cluster of six (pSer:5; pThr:1) high scoring, apparently
alternatively and multiply-phosphorylated sites between residues 40
and 60 of this 164 amino acid protein, in which S40 and S41 were
likely ambiguous positions for a single phosphate. E4L/RP30, similarly,
contained a cluster of sites (pSer:3; pThr:1) located towards the C-
terminus of the protein. H4L/RAP94: This protein showed two pairs of
adjacent sites (SS and ST) located around the center of the protein's
linear sequence. While the former two may represent localization
ambiguity (Table S3), the latter two were found within a
diphosphopeptide and therefore appear to be simultaneously occu-
pied. Of the two subunits of the Vaccinia early transcription factor
(VETF) heterodimer: D6R/ETF1 (VETF small subunit) showed a single
site (pSer), close to the protein's C-terminus. The transcriptional
ATPase D11L/NTP1 also showed a single pSer.
A18R/H5R/G2R group
This complex serves in the regulation of late gene transcription
(Black et al., 1998), and H5R has apparently unrelated roles in DNA
replication and virion assembly. A18R and H5R are clearly virion-
associated (Table S2), and G2R was detected in virion preparations
by the Gershon group only. A single phosphorylation site was
found in G2R within our MV preparation, namely a pThr at the
penultimate residue of the protein. H5R: A total of nine sites
(pSer:8; pThr:1) were detected scattered through the H5R protein.
Of these, phosphorylation at S46/T47 could represent a localiza-
tion ambiguity in which the favored alternative would be S46
(Table S3). We did not detect the phosphorylation of virion-
associated H5R at the sites (Thr84/Thr85) found to be occupied
after incubating recombinant H5R with recombinant VPK1 under
in vitro kinase conditions (Brown et al., 2000). Phosphorylation
was not detected in protein A18R.
REDOX pathway
Within the REDOX/sulfhydryl bond/thiol transfer-related pro-
teome (comprising proteins O2L/GLRX1, G4L/GLRX2, E10R, A2.5L,
F9L), phosphorylation was detected in just one protein, namely
A2.5L. Three potential phosphosites were detected (pSer:1; pThr:2)
located in a cluster towards N-terminus of this 76 residue protein,
interleaving with the protein's two cysteines. All combinations of
monophospho and diphosphopeptide were detected, in ﬁve dis-
tinct peptide backgrounds, providing clear evidence of multiple
and alternative occupancies (with ambiguity in just one experi-
ment, Table S4).
DNA metabolism
We detected the intravirion phosphorylation of just one protein
with function in the DNA metabolism category, namely K4L
(nicking enzyme). K4L contained an apparent cluster of up to six
phosphosites (pSer:2; pThr:2; pTyr:2) in the Y381–T391 region
(close to the protein C-terminus, Fig. S1). Three sites within the
cluster 381-YSY represent, apparently, the ambiguous localization
of a single phosphate. The cluster T388/S389/T391 also represents,
most likely, the ambiguous location of a single phosphate whose
most probable location is S389 (Table S3).
Proteinases
Vaccinia encodes contains two known proteinases, both shown
to be virion-associated (Table S2). Phosphorylation was found,
here, in both proteins. Within G1L (metalloproteinase), two sites
were detected (both pSer), one towards the center of the protein
and the other towards the C-terminus. Within I7L (core cysteine
proteinase), A single site (pSer) was detected, located towards the
center of the protein.
Defense
Phosphorylation was found within three proteins related to the
combating of host defenses, namely: C3L/VCP (complement path-
way inhibitor/complement control protein): Ours is the only group
to have detected this protein in MV preparations (Table S2), and it
contained a single phosphorylation (at pSer) being detected in the
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protein. The remaining two defense proteins have not been
detected in MV previously, by any group. These are: B8R (soluble
gamma IFN receptor, one pSer); and B13R/SPI2 (inhibits IL1beta-
converting enzyme, one pThr).
Role in IV-MV transition, protein detected in MV
A single phosphopeptide was detected from protein A6L (a
virion core protein with an essential role in virus maturation
(Meng et al., 2007), which was detected in MV by some groups but
not others, Table S2). This phosphopeptide contained two phos-
phosites, at residues Thr112 and Ser118.
Proteins of unknown function, previously detected in MV
preparations
A single pThr was detected in protein F8L, which has been detected
in MV preparations by all groups (Table S2). Four phosphosites were
detected in protein A19L, which has been detected in MV preparations
by some groups not others, Table S2 (pSer:3; pThr:1).
Other proteins of known function, not previously detected in MV
preparations
Phosphorylation was found in three proteins that have not
previously been detected in MV preparations by any group (Table S2).
Two of them, with roles as transcription factors in the infected cell,
are: A23R/VITF3 (a single triphosphopeptide spanning S117/S118/
Y122) and A1L/VLTF2 (a single pSer). The third was A44L/3BHS
(3 beta-hydroxysteroid dehydrogenase/Delta 5-4-isomerase), in
which a single pSer was detected.
Proteins of unknown function, not previously detected in MV
preparations
Phosphorylation was found in ﬁve proteins of unknown func-
tion that have not previously been detected in MV preparations by
any group (Table S2). These were: B18R (ankyrin repeat-containing
protein)—a single pTyr; protein N2L (bcl2-like)—a single pTyr; A47L
—a single pSer; V018 (predicted protein): a single triphosphopep-
tide (pSer:2; pTyr:1); and ﬁnally a small orf, namely D orf A,
containing a single pSer.
Phosphorylation site analysis
Amino acid composition within phosphorylated regions
The phosphopeptides listed in Table S4 did not, by any means,
fully cover each protein in which they were found. Possible
technical reasons for this are typical of any MS experiment, and
might be exacerbated by the range of protein and phosphopeptide
abundances encountered in the virion (above). Partial coverage
may also have been dictated by “hotspots” of biological phosphor-
ylation. In a preliminary test for the latter, amino acid composition
was calculated for the phosphopeptide contigs (Table S4) and their
encompassing whole proteins and, for each of the 20 common
amino acids, converted to a ratio of composition(contigs)/compo-
sition(whole proteins) (Fig. 3). The contigs were noticeably
enriched for Ser and Pro residues with respect to their parental
proteins, suggesting the occurrence of substantial Pro-dependent
Ser phosphorylation among packaged phosphoproteins. Pro-bias
may have resulted from these sites being resident within protein
loops, which may be intrinsically Pro-rich, and/or substrate recog-
nition by Pro-dependent kinases. Contigs were also enriched (to a
lesser extent) for T, D, N and Q.
Kinase recognition—VPK2
Substrate preference by the Vaccinia kinase VPK2 may arise
from steric factors (e.g. preference for proteins within the 7-
member complex of which VPK2 is a part, proximal complexes,
accessible loops within protein tertiary structures, etc.), or from
the recognition of a target sequence. To explore the latter, all
phosphorylation sites identiﬁed in the current study occurring
within proteins known, from prior studies, to be VPK2 substrates
(Table 1, Table S1), were collated as a set of 26 sequence segments
(Fig. S3). No obvious pattern was discerned by eye within this
group, other than a preponderance of Pro and Ser residues
(consistent with the MV phosphoproteome as a whole, Fig. 3)
and also the frequent occurrence of SSP and SP (with phosphor-
ylation occurring at the ﬁrst Ser). Any information within this set
related to VPK2 recognition is accompanied, presumably, by noise
from sites whose phosphorylation was VPK2-independent. To
explore this, we developed an approach (described in Supplemen-
tary materials) in which each sequence segment was scored
according to its distance from a consensus for all segments. After
elimination of the lowest scoring segment, the process of scoring
and elimination was repeated for all remaining segments. In this
manner, segments were eliminated iteratively, establishing a
ranking of “consensus-breaking” tendency. Combined rankings
from three scoring schemes (Supplementary materials) estab-
lished an aggregate score for each segment from which an
ascending series of scores was generated corresponded to the
original 26 segments (Fig. S4). Inﬂexions in the ascending series
suggested four nested sub-groups of potential VPK2 substrates in
addition to the starting group (Fig. S4), each sub-group represent-
ing a progressively stronger consensus. Fig. 4 shows, graphically,
the sequence consensus within the initial series and sub-groups 1,
2 and 3. Sub-group 2 contained representatives of all the proteins
known to be VPK2 substrates, and sub-group 3 contained repre-
sentatives of all except A14L. The consensus became noticeably
more information-rich by sub-group 3 with a noticeable predilec-
tion for an S, P or G residue immediately to the C-terminal side of
Fig. 3. Amino acid composition of phosphopeptide-containing contigs divided by
that of their encompassing whole proteins, expressed as a ratio for each of the 20
common amino acids. A higher ratio for a given residue type indicates its
enrichment in phosphopeptide-containing contigs. Despite the contigs not per-
fectly bracketing phosphorylated regions (contig ends being deﬁned by trypsin
cleavage sites), they were clearly enriched for Ser and Pro with respect to their
parental full protein sequences (see text). Contigs were also enriched (to a lesser
extent) for T, D, N and Q. With regard to D (Asp), phosphopeptide enrichment
procedures are known to co-enrich for acidic peptides. The relatively low
representation of Cys-containing phosphopeptides may have arisen from the
non-use of oxidized Cysteine as a Mascot search parameter.
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the phosphorylation site and a preference for Pro at the subse-
quent residue to the C-terminal side. Additional residue prefer-
ences were also apparent (Fig. 4).
In an attempt to ﬁnd any additional VPK2 substrates in the
conservative MV proteome, a scoring matrix representing the
consensus for sub-group 3 sites was applied globally. Using this
matrix, no new sites scored higher than the segments already
contributing to sub-group 3, though sites within the E4L/RP30
RNA polymerase subunit scored immediately below, along with
D8L residue T243 (data not shown), raising the possibility that
these may be VPK2 substrates. Using the looser sub-group
2 matrix, the E4L/RP30 and D8L sites again scored immediately
below the known members of sub-group 2, along with sites in
RNA polymerase subunit A5R/RP19 (data not shown), reinforcing
the possibility that Vaccinia RNA polymerase is a VPK2 substrate.
Kinase recognition—All known kinase families
To infer whether speciﬁc sites in the conservative MV phospho-
proteome might be attributable to cellular kinases, all sites were
searched against an atlas of known kinase-family consensus sequence
motifs (Miller et al., 2008). This resulted in 71matches with a posterior
probability of Z0.3 (considered a stringent threshold), within which
58MV phosphorylation sites were assigned to 12 kinase groups (some
sites being assigned to multiple groups). 72% of the assignments were
to just three major kinase groups (Table 2), namely CDK2/CDK3
(21 sites, covering nearly 30% of the high probability site assignments),
p38 (16 sites) and CK2 (14 sites). Fig. S4 shows, graphically, the
consensus for each of these three major kinase groups among the
matching Vaccinia sites.
Among these groups, the CDKs (cyclin-dependent kinases) are
primarily cell cycle-related in all organisms and have the con-
sensus site [S/Tn]PX[K/R] in which the starred residue is phos-
phorylated (Errico et al., 2010). Some Vaccinia sites were candidate
CDK substrates presumably as a result of a Pro residue following
the site of phosphorylation. Indeed, ﬁve members of the CDK-
matching group were shared with VPK2-substrate-protein sub-
groups (Fig. S2, Table 2), indicating that VPK2 might be “CDK-like”
in substrate recognition (albeit the only known phylogenetic
relatives of VPK2 are its homologs in other poxviruses (Punjabi
and Traktman, 2005)). Alternatively, cell cycle regulators may have
a role in Vaccinia virion assembly and/or release. Casein kinase 2
(CK), an S/T kinase, has also been implicated in cell cycle control
and DNA repair. CK2α1 phosphorylates acidic proteins such as
casein (Marin et al., 1992, Fig. S4). Two members of this group
were shared with VPK2-substrate-protein sub-groups (Fig. S2,
Table 2). p38 Mitogen activated protein kinases are responsive to
stress stimuli such as cytokines, UV, heat/osmotic shock, apoptosis
and autophagy (Sheridan et al., 2008). Vaccinia matches to p38
showed a dominating “P” after the phosphorylation site (Fig. S4).
Phosphorylation changes during virion activation
Vaccinia early transcription occurs within the infecting virus
particle. In vitro, virus envelope removal with nonionic detergent
accompanied by sulfhydryl reduction leads to the activation of
virion cores for early transcription accompanied, immediately,
by the phosphorylation of virion proteins (Moussatche et al.,
1991). In apparent contrast to this, active VH1 phosphatase is also
a requirement for early transcription, insofar as VH1-deﬁcient
virions are impaired in early transcription (Liu et al., 1995). Three
of our seven MV phosphoproteome experiments addressed the
phosphorylation/dephosphorylation of virion proteins upon virion
activation in vitro (Fig. 2). Virions were treated with nonionic
detergent/disulﬁde reducing agent in either HEPES buffer alone (in
one experiment) to address virion protein dephosphorylation, or
HEPES buffer supplemented with Mg.ATP (in replicate experi-
ments) to allow intravirion kinase activation in addition to depho-
sphorylation. In each experiment, the soluble and core-particulate
fractions remained unseparated. Each experiment employed three
aliquots of puriﬁed virion, one of which remained untreated. For
the dephosphorylation experiment, nonionic detergent concentra-
tions of either 0.05% or 0.5% were used for the remaining two
aliquots, reﬂecting conditions used in prior studies (Kates and
Beeson, 1970; Moussatche and Keller, 1991; Shuman and Moss,
1989). These two conditions will be referred to as “stripped cores”
and “etched cores”, on the basis of AFM images indicating the
gradual permeabilization of cores after virion envelope removal,
with permeabilization (or “etching”) being more pronounced at
higher detergent concentrations (Kuznetsov et al., 2008). For each
of the kinase activation experiments, the remaining two aliquots
were treated with Mg.ATP at a pH of either 7.0 or 8.5 (Fig. 2). In
each experiment, the activation period was terminated by dissolu-
tion and trypsinization of the three virus aliquots and differential
stable isotope labeling of the resulting peptide samples. Pooling of
all labeled peptides from an activation experiment was followed
by phosphopeptide enrichment and nanoLC-MS/MS with
precursor-level quantitation (Fig. 2). For each conﬁdently identi-
ﬁed phosphopeptide that was also conﬁdently quantiﬁable, rela-
tive peak intensities were calculated in the peak triples arising
from isotope labeling. Quantitation results are given in Table S5
after normalization as described in Table S5 legend.
Conﬁdent quantitation was achieved for only a subset of the
complete set of the identiﬁed phosphopeptides in Tables S3 and S4,
with the majority of the quantative information arising from
Fig. 4. Sequence Logo analysis of the regions surrounding sites of phosphorylation within known (Table 1, Table S1) VPK2 substrates. Three sub-groups show the distillation
of information after progressive elimination of the most consensus-breaking sequence segments (Fig. S2).
J. Matson et al. / Virology 452-453 (2014) 310–323 317
experiment “kinase2” due to the greater intensity of precursor-level
MS peaks. In our interpretation of data, all quant ratios within a 3-
fold range were discounted (regarded as “unchanged”). In this context,
quantitation data, protein-by-protein, were as follows:
A6L: Protein A6L showed a strong virion kinase activation-
dependent phosphorylation at residues S118 and/or S121, stronger at
pH 7.0 than at pH 8.5. A5R/RP19: Upon virion kinase activation at pH
7.0, A5R/RP19 showed clear evidence of new phosphorylation at either
S49 or S50 (Table S5). L4R/VP8: Phosphopeptides were quantitated
containing L4R/VP8 phospho-residues S158, Y176 and S220. No
signiﬁcant change in phosphorylation was detected at S158 or Y176
during kinase activation, but signiﬁcant phosphorylationwas observed
at S220 under pH 8.5 kinase activation conditions at (Table S5). L4R/
VP8-S220 can be regarded, therefore, as a clear substrate for phos-
phorylation upon virion activation. A14L: A14L residue S85 was clearly
phosphorylated in response to virion kinase activation, more promi-
nently at pH 8.5 than at pH 7.0. Of the nine membrane proteins in
which phosphorylation sites were conﬁdently identiﬁed (above), only
in protein A14L was the phosphorylated region considered to be
internal with respect to the accompanying membrane (above). Since
S85 was identiﬁed in both activation and non-activation experiments
(Table S3), this site was apparently partially occupied prior to virion
activation.
A13L: Upon virion kinase activation, A13L showed increased site
occupancy at residues T48 (pH 7.0) and S61 (pH 8.5). Virion activation
under non-kinase condition was accompanied by an over-abundance
of an A13L monophosphopeptide containing residue S40, suggesting
the possible dephosphorylation of another (undetected) residue
within this phosphopeptide. A13L phosphorylation inside the infected
cell is VPK2 and VH1-independent (Table 1).
Results for other proteins are discussed in Supplementary data
(“Phosphorylation changes during activation—other proteins”).
Discussion
Prior to the current study, to the best of our knowledge, two
in vivo sites of phosphorylation had been clearly identiﬁed among 11
reported Vaccinia phosphoproteins (Table 1) using approaches other
than MS analysis. Here, in a bottom-up phosphopeptide MS analysis,
we identiﬁed, conservatively, up to 189 phosphorylation sites among
48 proteins in Vaccinia mature virion preparations (Table S4). We
used a “strategy of variation”, with different experiments revealing
overlapping sets of phosphopeptides. No extracellular virion (EV)-
speciﬁc peptides or phosphopeptides were identiﬁed, consistent
with our exclusive use of MV. Our conservative dataset included
phosphopeptides from nine of the 11 previously-reported Vaccinia
phosphoproteins, the two exceptions being proteins I3L and E8R
(Table 1, Table S4). Although these two proteins have been reported,
unanimously, to be virion-associated (Table S2), E8R may be con-
sidered a phosphoprotein solely on the basis of an in vitro kinase
assay (Table S1). Our data conﬁrm and extend prior understanding of
MV protein phosphorylation, with a few similarities and differences.
Differences may arise from factors that include: (a) Phosphorylation
changes during either cell harvesting, generation of cell extracts and/
or virus puriﬁcation; (b) phosphorylation changes during the virion
lifecycle (assembly, maturation, exit, release); (c) differential sensi-
tivity of MS and non-MS based assays; (d) incomplete protein
coverage via MS; (e) prior use of context-speciﬁc anti-phospho-
residue antibodies. Protein-by-protein, similarities and differences
are summarized in Supplementary data (“Similarities/differences
between current (MS-based) and prior phosphorylation data”).
Our conservative MV phosphoproteome contained 10 proteins
not previously detected in Vaccinia MV, and with no obvious
biological role therein. These included the product of a small
Vaccinia ORF, YVDA (Tables S3 and S4) which is conserved
between Vaccinia strains. The products of smaller ORFs may be
less easily detectable by MS due to a paucity of trypsin sites, fewer
choices of peptide from which to identify them and fewer
phosphorylation targets. Due to our use of stringent score thresh-
olds, most or all of the 10 proteins are likely bona ﬁde phospho-
proteins. It is unclear whether these phosphoproteins are
packaged in MV at very low abundance or were trace contami-
nants in MV preparations. However, due to the wide abundance
dynamic range of ion trap MS, the detection of trace-contaminants
might be expected, even in 2x-banded MV preparations. Moreover,
the detection of trace contaminants might be exacerbated, here, by
phosphopeptide enrichment steps, which would tend to concen-
trate lower abundance peptides while depleting a background of
higher abundance (non-phospho) peptides. In addition, with fast,
Table 2
High conﬁdence matches of sites in the conservative MV phosphoproteome to human kinase consensus motifs. In column 3, the number of sites is given in parentheses after
the protein name.
No. of members In Vaccinia proteins
MAJOR
CDK2_CDK3 group 21 A11 (1), A13 (1), A4 (2), A9 (1), ETF1 (1), G2 (1) and G7
(2, one of which is in VPK2 sub-group 3), H5 (1), p4a (2), RP30 (2),
F8 (1), F17 (2, in all VPK sub-groups), K4 (1) VP8 (2), VPK2 (1, in all VPK2 sub-groups)
p38 group 16 A11 (1), A13 (1), A4 (2), ETF1 (1, same site as in CDK group), G2
(1, same as in CDK group)), G7 (2, one in VPK2 sub-group 3;
same sites as in CDK group), H5 (1), p4a (1), p4b (1), RP30 (2),
F8 (1), F17 (2, both in all VPK2 sub-groups, 1 in CK2 group)
CK2 group 14 A11 (1), A26 (1), A4 (1), H5 (2), p4a (3), p4b (2), RP19 (2), VPK2
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sensitive MS instrumentation identifying peptides in descending
order of ion intensity, it is possible to dig more deeply into a
proteome when it is a relatively simple one, such as that of a
virion.
While the numbers of phosphates within each identiﬁed
phosphopeptide is conﬁdently ascertained on the basis of experi-
mental peptide mass, positional location can be more ambiguous,
for example where fragmentation ion series are incomplete, and/
or where closely-spaced phosphorylation sites provide few frag-
mentation ions to distinguish candidate phosphate positions. Did
the phosphopeptide positional isomers in our dataset represent
alternative sites within a protein, or ambiguous localization of a
single site? With the use of conservative thresholds, a liberal
interpretation was adopted that positional isomers represented
genuinely alternative sites unless they were the alternate progeny
of a single Mascot query of a single mass spectral peak in a single
spectrum. There is considerable precedent for the phosphorylation
of multiple, closely-spaced sites in proteins, often by the same
kinase. Examples would include the phosphorylation of ribosomal
protein S6 by p70-S6 kinase at a cluster of four sites within a 10-
residue stretch (Ferrari et al., 1991) and the tyrosine phosphoryla-
tion of c-Raf protein at two adjacent sites (Fabian et al., 1993). In
another example, MAPKs are phosphorylated by dual speciﬁcity
MKKs at both the Thr and Tyr residue within a TXY sequence
(Gartner et al., 1992; Payne et al., 1991). There is also substantial
precedent for the hierarchical phosphorylation of closely spaced
sites within substrates by distinct kinases: Casein kinase 1 (CK1),
Glycogen synthase kinase (GSK) and to a lesser extent casein
kinase 2 all prefer substrates that have been “primed” at nearby
sites by other kinases: Positioning requirements are kinase-spe-
ciﬁc, with CK1 preferring a pSer/pThr at position -3 relative to its
own phosphorylation site, and GSKs requiring a pSer/Thr at
position þ4. Well-known examples of CK1 and GSK3 substrates
phosphorylated in this manner include beta-catenin in the Wnt
signaling pathway (Cohen and Frame, 2001).
Employing both tryptic and semi-tryptic speciﬁcity for database
searches, the conservatively thresholded dataset contained a num-
ber of high conﬁdence semi-tryptic peptides (those that were
tryptic at one end only) from proteins of various classes. Non-
trypsin proteolysis occurred, apparently, at some point in time
between virion morphogenesis and MS analysis. Semi-tryptic pep-
tides did not appear, or show changes of abundance, as a result of
virion activation (Fig. 2, gray, data not shown). One possibility might
be the “nicking” of MV proteins during virus preparation steps that
exposed virus to cellular extract. Another possibility, namely
source-level fragmentation of peptides at the mass spectrometer
inlet could be discounted for the great majority of semi-tryptics,
since only a small minority co-chromatographed with correspond-
ing tryptics during nanoLC-MS/MS (data not shown).
In most instances, semi-tryptic peptides were co-terminal (ﬂush)
at the fully-tryptic C-terminus and nested at the N-terminus, with
nesting originating close to a bona ﬁde tryptic N-terminus (Table S4).
This suggests aminopeptidase activity. With aminopeptidases being
zinc metalloenzymes, one possibility might be that the Vaccinia G1
zinc metallopeptidase (which is packaged) is such an enzyme and,
after solubilization and release, retains some activity towards tryptic
peptides during the extended trypsinization of MV proteins. This has
not been tested. Irrespective of origin, the presence of semi-tryptics
was an asset to the experiment, acting to conﬁrm sites of phosphor-
ylation within distinct background sequence environments.
Changes in phosphopeptide abundance as a result of virion
activation, were measured. The resulting quantitative MS dataset
was by no means complete, with a number of phosphopeptides likely
below the below limit of quantitation. This area would likely beneﬁt
from a more exhaustive study. However, phosphopeptide quantitation
data that were available (Table S5) proved to be generally reproducible
as afﬁrmed by multiple quantitation data points (not shown) for the
same peptides in various chromatographic fractions alongwith various
charge states/peripheral modiﬁcation states contributing to the given
mean values. Spectral interference issues were likely defrayed by the
emptier chromatograms arising from a relatively simple starting
proteome that was further simpliﬁed via phosphopeptide enrichment,
contributing to reproducibility in quantitation. As a further aid in
accurate quantitation, normalization procedures were employed to
isolate quant changes as far as possible to the phosphate group itself.
In each clear observation of phosphorylation changes as a result
of virion kinase activation, the response was pH-biased (Table S5,
Table 3) hinting at multiple pathways of intravirion protein phosphor-
ylation. Insofar as puriﬁed VPK1 (B1 kinase) and puriﬁed VPK2 (F10
kinase) are activated at pH 9.0 (Lin et al., 1992) and pH 7.5 (Lin and
Broyles, 1994) respectively, sites showing bias towards pH 8.5 and pH
7.0 activation could be VPK1 and VPK2 substrates, respectively. Within
the known VPK2 target list (Fig. S2), only A14L-S85 could be quantiﬁed
and, according to the above metric, it showed VPK1 bias (Table S5,
Table 3). In this regard, A14L was lost from our VPK2 “order of
elimination” series earlier than the other known VPK2 substrates (Fig.
S3). Moreover, A14L was the only virion membrane phosphoprotein in
our dataset whose phosphorylation sites were apparently internal
with respect to the accompanying membrane. With regard to Vaccinia
early transcription, evidence has been shown (Moussatche and Keller,
1991) for pH-biased phosphorylation of 70 and 80 kDa proteins
during virion activation, with phosphorylation occurring primarily at
pH 7.0. 70 and 80 kDa are consistent with the known sizes of the
two VETF subunits. Albeit quantitative data were not obtained for
VETF phosphopeptides in our experiments, activation-dependent
phosphorylation of RNA polymerase subunits was detected, notably
in A5R/RP19. According to the above metric for pH-dependence, A5R/
RP19 would be a VPK2 substrate (Table 3).
Conclusions
In summary, in a deep analysis using a strategy of variation, we
have unearthed up to 189 phosphorylation sites in 48 proteins in
Vaccinia MV preparations with high conﬁdence. This may repre-
sent more sites than have been found before in any virus particle.
The current study provides a basis for the further investigation of
phosphorylation during Vaccinia virus infection.
Materials and methods
Materials
Iodoacetamide, triethylammonium bicarbonate (TEAB), trypsin,
ethyl acetate, triﬂouroacetic acid (TFA), glycolic acid, sodium N-
Table 3
pH-dependent differential fold-change in phosphorylation upon activation, by
protein/phosphorylation site. Alternate ratios, where indicated, arise from either
different experiments or different normalization controls. Derived from Table S5.
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lauroylsarcosine, sodium deoxycholate, spermidine, NH4OH, piper-
idine, CH2O, CD2O, 13CD2O, NaBH3CN and NaBD3CN were
from Sigma Aldrich. Tris(2-carboxyethyl)phosphine (TCEP) and
KCl were from ThermoFisher Scientiﬁc, pyrrolidine was from
Alfa Aesar, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) was from Research Products International Corp., NaOH
was from EMD Millipore, ATP was from GE Healthcare Life
Sciences, MgCl2 was from Calbiochem, NP40 was from US Bio-
chemicals. Vaccinia strain WR virions were prepared and puriﬁed
as described (Malkin et al., 2003). Brieﬂy, vaccinia-infected HeLa
cells were recovered by centrifugation and subjected to hypotonic
lysis with dounce homogenization. After pelleting nuclei followed
by sonication, virus was pelleted through a 36% sucrose cushion.
The resuspended pellet was banded in a 5–40% continuous sucrose
gradient, and the harvested virus was collected, recovered and




350 μL (2109 PFU) aliquots of puriﬁed MV suspension
were centrifuged in a microfuge at full speed for 60 s, and super-
natants removed. Aliquot 1 (control) was resuspended in 40 mL of
50 mM HEPES-NaOH, pH 8.5 and placed on dry ice. Aliquot 2 (for
the generation of “stripped cores” (Moussatche and Keller, 1991;
Shuman and Moss, 1989)) was resuspended in 20 mL of 50 mM
HEPES-NaOH (pH 8.5) followed by the addition of an equal volume
of 2x low-NP40 uncoating buffer (100 mM HEPES-NaOH, pH 8.5,
0.1% NP40, 80 mM TCEP). Aliquot 3 (for the generation of “Etched
cores” (Kates and Beeson, 1970)) was also resuspended in 20 mL of
50 mM HEPES-NaOH (pH 8.5) followed by the addition of an equal
volume of 2 high-NP40 uncoating buffer (100 mM HEPES-NaOH,
pH 8.5, 1% NP40, 80 mM TCEP). After incubation of aliquots 2 and
3 for 10 min at RT 1C with occasional vortexing, aliquot 1 was
thawed and supplemented with 2.8 mL of 0.5 M TCEP, then all
three aliquots were supplemented with an equal volume of 2
dissociation buffer (72 mM sodium N-lauroylsarcosine (NLS),
24 mM sodium deoxycholate (DOC), 10 mM TCEP, 100 mM TEAB
(pH 8.0), plus 1 phosphatase inhibitor cocktail (BioVision
EZBlock Phosphatase Inhibitor Cocktail I). To solubilize proteins,
all three samples were subjected to three cycles of heating at 95 1C
(5 min) followed by sonication (5 min).
Virion kinase activation
3x75 μL aliquots (3109 PFU) of puriﬁed MV suspension were
centrifuged as above. The pellet from aliquot 1 (control) was
treated as above (leaving at room temperature). Pellets from
aliquots 2 and 3 were resuspended in 10 mL of 50 mM HEPES-
NaOH (pH 7.0 or pH 8.5, respectively) followed by addition of an
equal volume of 2 pH 7.0 low-NP40 uncoating buffer (100 mM
HEPES-NaOH, pH 7.0, 0.1% NP40, 80 mM TCEP) or 2 pH 8.5 low-
NP40 uncoating buffer (above), respectively. Incubation of aliquots
2 and 3 at room temperature for 5 min with occasional vortexing
was followed by the addition of an equal volume of 2 pH
7.0 phosphorylation buffer (50 mM HEPES-NaOH, pH 7.0, 80 mM
TCEP, 2 mM ATP, 2 mM MgCl2, 2 mM spermidine, 20 mM KCl)
or 2 pH 8.5 phosphorylation buffer (as above but with pH
8.5 HEPES-NaOH) to aliquots 2 and 3, respectively, and incubation
at room temperature for 15 min with occasional vortexing. After
incubation, aliquots were treated as above.
Other experiments (“100microL-”; “IMAC-”; “WayneLTQ”)
Aliquots of Vaccinia MV suspension (50–100 μL) were centri-
fuged at 14,000 g and storage supernatant discarded. Pellets
were supplemented with 1 dissociation buffer (12 mM NLS,
12 mM DOC, 5–10 mM TCEP, 50 mM TEAB (pH 8.0)) (Masuda et al.,
2008) then subjected to three cycles of heating at 95 1C (5 min)
followed by sonication (5 min).
Peptide-level protocols
Trypsinization, peptide extraction and cleanup
After addition of iodoacetamide to a ﬁnal concentration of
25 mM, samples were incubated in the dark for 30 min at room
temperature. Protein concentrations were then determined by BCA
assay (Thermo Pierce) following the manufacturer's protocol. After
a 5-fold dilution with 50 mM TEAB (pH 8.0), trypsin was added at a
ratio of 1:100 (w:w, enzyme:substrate). Following overnight
incubation at 37 1C, a second, equivalent aliquot of trypsin was
added and incubation extended for a further 3 h at 37 1C. Deter-
gent was removed by addition of an equal volume of ethyl acetate/
0.5% triﬂouroacetic acid (TFA) followed by vortexing for 5 min,
then centrifugation at 13–14,000g for 30–300 s to separate phases.
After discarding the organic phase, peptides were desalted using
either C18 (Experiment “WayneLTQ” (Rappsilber et al., 2007)) or
(for other experiments) sequential C18 and Hypercarb StageTips in
P-1000 pipette tips. C18 StageTips were made with four stacks of
C18 (3 M, Inc.) (Ishihama et al., 2006), and Hypercarb StageTips
were made from Hypercarb beads (Thermo Scientiﬁc) layered over
one stack of C8 (3 M, Inc.). In the ﬁrst step of StageTip peptide
cleanup, C18 stageTip-bound peptides were washed with 0.1% FA
then eluted with 80% CH3CN/0.1% formic acid (FA). Unbound
peptides in the load were passed through Hypercarb stageTips,
eluting with 80% CH3CN/0.1% FA followed by 200 mM pyrrolidine/
60% CH3CN. All stageTip elutions were pooled, dried under
vacuum and reconstituted in 100 μL of solution X (80% CH3CN,
1 M glycolic acid, 5% TFA in water) if used for TiO2 fractionation, or
1 mL of (250 mM acetic acid, 30% CH3CN, pH 3.0) if used for IMAC,
otherwise in 100 mM TEAB (pH 8.0).
Isotopic dimethyl labeling
Peptides from the previous step were isotopically labeled at
N-termini/lysine sidechains with either –CH3, –CD3 or –13CD3 by
mixing with either CH2O (light), CD2O (medium) or 13CD2O
(heavy) prior to addition of NaBH3CN (light, medium) or NaBD3CN
(heavy) (Boersema et al., 2009). After vortexing (60 min),
unreacted formaldehyde was quenched with excess primary
amine then excess formic acid. The three labeled samples were
pooled and the mixture desalted as for C18 and Hypercarb tips
(above), except using C18 Sep-Pak cartridges (200 mg, Waters)
and HyperSep Hypercarb cartridges (200 mg, Thermo Scientiﬁc).
Eluates were vacuum-dried then reconstituted in solution X.
Phosphopeptide enrichment, SCX
In one experiment (“WayneLTQ”), phase-separated, unlabeled
peptides, after a simple C18 StageTip cleanup (above) were
fractionated directly using stacked SCX-C18 StageTips with 3–6
salt cuts in the SCX fractionation step (Rappsilber et al., 2007).
Phosphopeptide enrichment, TiO2
Titanium dioxide (TiO2)-based enrichment columns were fab-
ricated from either a pipette tip plugged with a section of SDB
membrane (experiment “WayneLTQ”) or from a 200 μL GELoader
pipet tip plugged with a section of C8 membrane. TiO2 beads
(3 mg, Titansphere 5 μm, GL Sciences, Japan) were packed using
20 mL methanol (experiment “WayneLTQ”) or 80% CH3CN, 5% TFA
in water as transfer solution (Jensen and Larsen, 2007), centrifu-
ging at 14,000 g for 5 min to pack the beads (Sugiyama et al.
(2007) with slight modiﬁcation). The resulting columns were pre-
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equilibrated with 100 mL of 70% CH3CN, 29.9% lactic acid, 0.1% TFA
in water (solution A), centrifuged at 400 g for 5 min, repeating
once (experiment “WayneLTQ”), or with 5 μL of solution X, then
20 μL of 80% CH3CN, 1% TFA in water to wash away the glycolic
acid. The equilibrated tip was loaded with peptide sample in
100 mL of solution A, followed by centrifugation at 400 g for
5 min, after which beads were washed (experiment “WayneLTQ”)
with, sequentially, solution A (100 mL) then (80% CH3CN, 0.1% TFA,
100 mL) to remove the lactic acid. In other experiments, beads were
washed instead as for the pre-equilibration step. All experiments:
Peptides were eluted by the sequential addition of 20 μL aliquots
of 5% NH4OH in water, 5% piperidine in water, then 5% pyrrolidine
in water, into equivalent volumes of 10% TFA in water (Sugiyama
et al., 2007). Experiment “WayneLTQ”: TiO2 fractions were indivi-
dually desalted using C18 StageTips alone. Other experiments:
TiO2 fractions were individually desalted using C18 and Hypercarb
StageTips as described above, but on a smaller scale in which C18
tips were fabricated by placing a C18 disk in a 200 μL micropipette
tip, and HyperCarb tips were fabricated as for TiO2, using 200 μL
GELoader tips with a C8 disk inserted, and loading HyperCarb
beads into the tip. After desalting, the C18 and Hypercarb elutions
of each fraction were combined, evaporated to dryness, and
reconstituted in 10 μL of 0.1% FA in water.
Phosphopeptide enrichment, IMAC
80 μL of a resuspended 50% slurry of PHOS-Select Iron Afﬁnity
Gel beads (Sigma Aldrich) in water was placed onto the ﬁlter of a
0.45 mm nylon Nanosep MF Centrifugal Device (Pall Life Sciences)
and washed 3 with 0.5 mL of IMAC wash solution (0.25 M acetic
acid, 30% CH3CN in water) by mixing with the beads followed by
centrifugation for 30 s at 8000g. Desalted/reconstituted peptide
sample (above) was added to beads in two aliquots, each addition
followed by incubation at room temperature for 60 min with
inversion mixing then centrifugation for 30 s at 8000g. Beads
were then washed once with 0.5 mL of IMAC wash solution and
once with H2O, each wash followed by centrifugation for 30 s at
8000g. Peptides were eluted with 0.5 mL of 0.4 M NH4OH, 30%
CH3CN in water then 0.5 mL of 0.2 M sodium phosphate (pH 8.4),
in water. For each elution, beads were incubated for 5 min with
inversion then centrifuged for 30 s at 8000g. Eluates were acidiﬁed
immediately then desalted individually, as described above
(“Phosphopeptide enrichment, TiO2”).
NanoLC-MS/MS, database searching and data processing
Phosphopeptides were analyzed on either the LTQ Classic mass
spectrometer with CID fragmentation or the LTQ Velos Pro mass
spectrometer with ETD capability. In either case, samples were
injected to a 75 μm or 100 μm150mm C18-packed nanospray tip
in 2–5% CH3CN, 0.1% formic acid, eluting during nanospray ESI-LC-MS/
MS with a gradient of 2–95% CH3CN in 0.1% formic acid, over 3 h.
Instrument methods for the LTQ Classic picked the 3–7 most intense
ions in precursor spectra in the context of dynamic exclusion, for CID
fragmentation via either multistage activation or neutral loss-triggered
MS3. Instrument methods for the LTQ Velos Pro picked the 10 most
intense multiply-charged ions in precursor spectra in the context of
dynamic exclusion, for alternating pairs of MS2 scans with the
alternating MS2 scan pairs employing either HCD/ETD or CID/ETD
fragmentation modes. ETD scans employed supplemental activation.
For quantitative (virion activation) experiments, data were acquired in
proﬁle mode, and for other experiments in centroid mode.
NanoLC-MS/MS spectral raw ﬁles were processed into individual
peaklist (.mgf) ﬁles (or into a single merged.mgf for all raw ﬁles from
experiment “WayneLTQ”) using Mascot Distiller 2.4 (Matrix Science).
Mascot Server 2.4 (Matrix Science) was used for peaklist searches
against three databases, namely the target database (SwissProt
2012_03, selecting Vaccinia WR or humanþVaccinia taxonomy), a
database of common contaminants, and a decoy database of random
sequences of equivalent composition, selecting either tryptic or semi-
tryptic speciﬁcity and up to 1 missed cleavage (Table S6). A single ﬁxed
modiﬁcation was selected, namely cysteine carbamidomethylation.
Variable modiﬁcations comprised methionine oxidation, deamidated
(NQ), serine/threonine phosphorylation and tyrosine phosphorylation.
Precursor mass tolerance was 0.25 Da allowing 2þ/3þ charge,
MS/MS fragment mass tolerance was 0.5 Da, 13C¼0 (see Table S6 for
full listing of search, report and export settings). Mascot Server search
reports were re-thresholded by adjusting FDR (decoy:target hits ratio)
to either 1% or 5% before generation of protein- and peptide-level
exports (Table S6). The resulting protein- and peptide-level exports
were reformatted, sorted, merged, ﬁltered, condensed, enumerated,
interpreted, and ﬁgures were generated, using in-house software
(Supplementary methods).
For conﬁdence in phosphosite localization, Mascot Server 2.4 pro-
vided “site_analysis” conﬁdence (SAC) values (for SAC, Mascot exports
adopted the header “pep_var_mod_conf”, Table S3) following the
method of ref. (Savitski et al., 2011). SAC values equated most simply
to 1(10\widehat(MV))100%, where M is the Mascot Delta
score (“MD-Score” of ref. (Savitski et al., 2011)) and V is nominally 0.1
(equating an MD-score of 10 to a conﬁdence of 90%). However, in
practice, V was iterated during each calculation to achieve a sum of
100% for the SAC values corresponding to the MD-scores of the ten
best peptide-spectrum matches.
For precursor-level quantitation (virion activation) experiments,
database searching employed exclusive modiﬁcations comprising
heavy, intermediate, and light dimethyl labels on peptide lysine side
chains and N termini (Boersema et al., 2009) and quant ratios were
calculated in Mascot Distiller after spectral peak ﬁtting and peak area
determination for the ﬁtted model. Data from Mascot Distiller were
exported using signiﬁcance thresholds corresponding to 1% FDR (as
employed in Mascot Server, above). Exported quant values were
treated and analyzed using in-house software as described (Chou
et al., 2012), except that each distinct peptide species was considered
to be quantitatively independent (as opposed to grouping/averaging
by protein accession). Quant ratios were discarded for all peptide
species without multiple quant determinations, and any outlying
quant values among multiple determinations were validated visually
then discarded if necessary (Chou et al., 2012). Final quant ratio values
adopted the geometric mean of individual determinations.
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